GleamWall
中文EN

CNSY CERENOME, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1095981 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-32.9%
TTM net income YoY-47.4%
TTM EPS YoY143.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-832.6%
Net margin-859.5%
FCF margin-813.5%
EBITDA margin-817.7%

Returns

ROE-1,468.0%
ROA-196.4%
ROIC (approx.)—
Asset turnover0.23x

Leverage & solvency

Liabilities / assets107.6%
Debt / equity—
Current ratio0.61x
Interest coverage-815.92x

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-19.6%
Payout ratio—
Capex / revenue39.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$722,000$411,000$1.03M$1.37M$1.40M$1.39M$1.06M$1.41M
R&D expense$2.11M$4.26M$2.87M$2.94M$2.44M$1.25M$1.76M$2.19M
SG&A expense$5.16M$5.20M$5.28M$4.17M$3.44M$1.68M$2.84M$3.13M
Operating income-$7.46M-$9.06M-$7.12M-$5.74M-$4.48M-$1.54M-$3.54M-$3.90M
Interest expense$14,000$5,000$17,000$0$0$0$548,000$57,000
Net income-$8.66M-$9.01M-$6.95M-$5.71M-$4.42M$5.15M-$17.40M-$3.90M
EBITDA-$7.31M-$8.92M-$7.02M-$5.60M-$4.41M-$1.46M-$3.39M-$3.70M
EPS (basic)-1.14-1.31-1.05—-1.030.62-29.86—
EPS (diluted)-1.14-1.31-1.05—-1.03-0.16-29.86—
Weighted avg. shares (diluted)7.57M6.90M6.65M—4.30M8.37M582,668—
Balance sheet
Cash & equivalents$879,000$2.37M$3.02M$4.26M$13.29M$2.23M$9.87M$76,000
Short-term investments$3.99M$6.22M$12.09M$4.36M$3.31M$4.65M—$3.53M
Receivables$722,000———————
Inventory$235,000———————
Current assets$8.07M$11.77M$18.03M$14.85M$17.59M$9.21M$10.87M$5.26M
PP&E, net$1.35M$1.41M$1.01M$257,000$273,000$289,000$324,000$448,000
Goodwill$372,000$372,000$372,000$372,000$372,000$372,000$372,000$372,000
Intangibles———$333,000———$469,000
Total assets$12.20M$14.03M$19.92M$16.32M$18.67M$10.35M$12.06M$6.63M
Current liabilities$13.12M$8.57M$7.96M$12.31M$13.62M$7.32M$10.56M$15.55M
Total liabilities$13.12M$8.57M$7.96M$12.33M$13.62M$7.32M$35.70M$15.58M
Shareholders' equity-$923,000$5.46M$11.96M$4.00M$5.05M$3.03M-$23.64M-$8.95M
Shares outstanding7.88M7.31M6.86M5.55M131.61M92.18M17.00M5.90M
Cash flow statement
Operating cash flow-$7.67M-$7.13M-$6.24M-$6.26M-$2.55M-$5.80M-$6.17M-$1.21M
Capital expenditure$51,000$499,000$818,000$30,000$27,000$7,000$3,000$11,000
Free cash flow-$7.72M-$7.63M-$7.06M-$6.29M-$2.58M-$5.80M-$6.17M-$1.22M
Investing cash flow$2.00M$5.37M-$8.53M-$1.08M$1.30M-$4.63M$3.56M$64,000
Financing cash flow$4.18M$1.11M$9.04M$2.80M$12.31M$2.80M$12.40M$0
Depreciation & amortization$145,000$137,000$96,000$145,000$77,000$77,000$146,000$199,000
Stock-based compensation$709,000$830,000$1.02M$713,000$527,000$152,000$148,000$128,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.